After radiation therapy for prostate cancer, the prostate gland gradually shrinks, its internal tissue structure becomes less defined, and PSA levels slowly decline over months to years. But the changes extend well beyond the gland itself. Radiation affects the bladder, rectum, sexual function, fertility, and even hormone levels, with some effects appearing within weeks and others emerging years later.
The Prostate Gland Itself Changes
Radiation damages the DNA of both cancer cells and normal prostate tissue, triggering cell death over time. The gland responds by shrinking and becoming more uniform in texture. On MRI, a radiated prostate shows decreased size and a diffusely altered appearance, with the normal zones of the gland (peripheral, central, and transition) becoming harder to distinguish from each other.
This matters for follow-up imaging. A dark spot on a post-radiation MRI might look concerning, but it can simply represent treated, nonviable tumor tissue rather than active cancer. Radiologists use specialized techniques, including contrast-enhanced imaging and diffusion-weighted scans, to tell the difference. Recurrent cancer typically shows up as a distinct nodule that lights up with contrast, while treated tissue enhances slowly and faintly.
How PSA Levels Behave Afterward
PSA, the protein your doctor tracks as a marker of prostate cancer activity, doesn’t drop to zero after radiation the way it does after surgical removal of the prostate. Instead, it gradually declines to a lowest point called the nadir. For patients receiving radiation combined with hormone therapy, that nadir typically arrives within 3 to 6 months. For radiation alone, it can take 18 months or longer.
About 25% of patients experience what’s called a PSA bounce: a temporary rise in PSA that isn’t caused by cancer returning. The median time for this bounce is around 11 months after treatment, and roughly 86% of bounces happen within the first 6 months. These spikes can be anxiety-inducing, but they resolve on their own. Clinicians distinguish a bounce from true recurrence using the Phoenix criteria, which define biochemical recurrence as a PSA rise of at least 2 ng/mL above your lowest post-treatment level. That threshold was specifically designed to avoid false alarms from harmless fluctuations.
Urinary Side Effects: Early and Late
The bladder and urethra sit close to the prostate and inevitably absorb some radiation dose. Acute urinary symptoms, those appearing within the first 90 days, affect a significant number of patients. In a large clinical trial analysis, about 31% of men who received radiation to an intact prostate experienced moderate or worse acute urinary toxicity, including increased frequency, painful urination, and urgency.
These early symptoms usually improve within weeks to a few months after treatment ends. Late urinary effects are a different story. Defined as symptoms appearing more than 180 days after treatment starts, they can include blood in the urine, persistent frequency, or changes in urinary stream. One important finding from long-term studies: it takes at least 5 years of follow-up to see the nearly full expression of late urinary toxicity. In other words, new urinary symptoms can still emerge years after radiation.
What Happens to the Rectum
The rectum sits directly behind the prostate, making it vulnerable to collateral radiation exposure. The resulting inflammation, called radiation proctitis, comes in two forms.
Acute radiation proctitis develops during treatment or within six weeks afterward. Symptoms include rectal urgency, discomfort, and sometimes loose stools. Most cases resolve as the tissue heals.
Chronic radiation injury is less predictable. It can develop as a continuation of acute symptoms or appear with a delayed onset, anywhere from 9 to 14 months after radiation and occasionally decades later. Unlike the acute form, chronic radiation injury involves lasting damage to the rectal lining rather than active inflammation. The incidence varies widely depending on the radiation technique used. For seed implants (brachytherapy) alone, estimates range from 8 to 13%, rising to 21% when brachytherapy is combined with other treatments. Overall, chronic radiation injury to the rectum occurs in roughly 2 to 20% of patients.
Erectile Function Declines Gradually
Unlike surgery, which can cause immediate erectile dysfunction by damaging nerves near the prostate, radiation-induced erectile problems develop slowly. The mechanism is different: radiation damages the small blood vessels and smooth muscle tissue that enable erections, and this damage accumulates over months and years.
About 36% of men develop new-onset erectile dysfunction within two years of radiation. By three to five years after treatment, approximately half of patients experience some degree of erectile difficulty, depending on age, baseline function before treatment, and other health conditions like diabetes or cardiovascular disease. In one dose-escalation trial, of 51 patients assessed at two years, 12 remained fully potent, 22 had reduced potency, and 17 were impotent. The gradual nature of the change means some men initially feel reassured that radiation “preserved” their function, only to notice changes a year or two later.
Fertility and Hormone Levels
Even though radiation targets the prostate, the testicles are close enough to receive scattered dose. Testicular tissue is remarkably radiosensitive, with function affected by doses as low as 0.15 to 0.3 Gy (a fraction of the therapeutic dose aimed at the prostate).
A recent analysis of modern radiation techniques found that 84% of patients received enough scattered testicular dose to reduce sperm production, 65% reached the threshold for temporary loss of sperm production entirely, and 10% received doses above 2 Gy, which is likely to cause permanent infertility. Cumulative testicular doses above 2 to 2.5 Gy from fractionated radiation generally result in prolonged and likely permanent loss of sperm production. For men who want to father children after treatment, sperm banking before radiation is worth discussing.
Hormone production takes a hit too, though the cells responsible for testosterone (Leydig cells) are somewhat more radiation-resistant than sperm-producing cells. In a study comparing men 3 to 8 years after radiation versus surgery (none on hormone therapy), the radiation group had total testosterone levels averaging 27% lower, with corresponding increases in the pituitary hormones the body produces when it senses low testosterone. The precise dose at which this hormonal change becomes permanent isn’t yet clear, but the pattern suggests that radiation to the pelvic area can produce a mild, chronic testosterone deficit in some men.
Long-Term Risk of Secondary Cancers
Radiation therapy carries a small but real increase in the risk of developing a new, unrelated cancer in the treatment area. The organs most affected are the bladder and rectum, which absorb radiation during prostate treatment.
Compared to men treated with surgery alone, those who received external beam radiation had roughly 1.7 times the risk of later developing bladder cancer, based on studies with a median follow-up of nearly 12 years. The overall risk of any secondary cancer in the pelvic area increases over time: the hazard ratio climbs from about 1.24 in the first five years to approximately 1.5 between years 5 and 15 after treatment.
In absolute terms, the additional risk is small. At 25 years after treatment, the difference in secondary cancer rates between radiated and non-radiated patients is roughly 0.7 to 1%. For most men diagnosed with prostate cancer in their 60s or 70s, this incremental risk is a modest consideration weighed against the cancer-control benefits of radiation. For younger patients with decades of life expectancy ahead, it becomes a more meaningful factor in treatment decisions.